Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2021 Net Income-$1.22M-$1.22MN/M vs Q2 2021 EPS Diluted-$0.01-$0.01N/M vs Q2 2021 Operating Income-$1,059,893N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
derived
ended Jun 30, 2022 · filed Aug 16, 2022 · 47 d after period end